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Abstract The DNA sequence ncoding human placental thiore- 
doxin reductase has been determined. Of the 3826 base pairs 
sequenced, 1650 base pairs were in an open reading frame encod- 
ing a mature protein with 495 amino acids and a calculated 
molecular mass of 54,171. Sequence analysis showed strong sim- 
ilarity to glutathione reductases and other NADPH-dependent 
reductases. Human thioredoxin reductase contains the redox- 
active cysteines in the putative FAD binding domain and has a 
dimer interface domain not previously seen with prokaryote and 
lower eukaryote thioredoxin reductases. 
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doxin reductase is a potential target for the development of 
drugs to control abnormal cell proliferation. It is known that 
some antitumor quinone drugs [18], nitrosoureas [19], and the 
cell differentiating agent 13-cis-retinoic acid [20] are mecha- 
nism-based inhibitors of mammalian thioredoxin reductase 
which may contribute to their activity. 
E. coli thioredoxin reductase has been cloned and sequenced 
[21,22] and its biochemical and physical properties extensively 
studied [23,24]. Eukaryotic thioredoxin reductases have so far 
been only cloned from Penicillium chrysogenum [25], Saccharo- 
myces cerevisiae [26], and Arabidopsis thaliana [27] and they 
show 44-50% sequence identity to the bacterial enzyme. We 
now report the cloning and sequencing of a putative thiore- 
doxin reductase from human placenta. 
1. Introduction 2. Materials and methods 
Regulation of the intracellular redox environment is a feature 
of all cells. A redox enzyme that plays an important role in cell 
proliferation is thioredoxin reductase (EC 1.6.4.5). It is a mem- 
ber of the pyridine nucleotide-disulfide oxidoreductase family 
that includes glutathione reductase, lipoamide dehydrogenase, 
mercuric ion reductase and NADH peroxidase [1]. Members of 
the family are homodimeric proteins, each subunit of which has 
a redox active disulfide site and a tightly, but non-covalently 
bound FAD group that mediates the transfer of reducing equiv- 
alents from NADPH to a disulfide bond of the enzyme, and 
then to the disulfide bond of the substrate. 
Physiological substrates for thioredoxin reductase are the 
redox proteins thioredoxin [2] and protein disulfide isomerase 
[3]. There may be other substrates but they remain to be iden- 
tified [4]. Thioredoxin reductase has diverse functions in the 
cell. Through thioredoxin it provides reducing equivalents for 
ribonucleotide r ductase, the first unique step in DNA synthe- 
sis [5], for methionine sulfoxide reductase [6], and for vitamin 
K epoxide reductase [7]. Thioredoxin also catalyzes protein 
folding [3] and exerts specific redox control of some transcrip- 
tion factors to modulate their binding to DNA. Transcription 
factors regulated in this way include NF-lcB [8,9], TFI I IC [10], 
BZLF1 [11], and the glucocorticoid receptor [12]. The tran- 
scription factor AP-1 (Fos/Jun heterodimer) is subject o redox 
control by the nuclear redox factor Ref-1 which, in turn, is 
reduced by thioredoxin [13]. Thioredoxin has also been found 
to stimulate the growth of a variety of normal and cancer cell 
lines in culture [14-17]. The redox activity of thioredoxin is 
essential for its cell growth stimulating activity [16,17] and 
thioredoxin may be reduced by a thioredoxin reductase on the 
surface of cells [17]. 
Because of its role in cell proliferation, mammalian thiore- 
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Human thioredoxin reductase was purified to homogeneity from 
human placenta s we have previously described [28] and amino termi- 
nal and internal amino acid sequences of the tryptic digest obtained 
(W.M. Keck Foundation, Biotechnology Resource Laboratory, New 
Haven, CT) as follows: N-terminal sequence, Gly-Pro-Glu-Asp-Leu- 
Pro-Lys-Ser/Lys-Tyr; internal sequences, Phe-Leu-Ile-Ala-Thr-Gly- 
Glu-Arg-Pro, and Val-Val-Gly-Phe-His-Val-Leu-Gly-Pro-Asn-Ala- 
Gly-Glu-Val-Thr-Gln-Gly-Ph e-Ala-Ala-Ala-Leu-Lys. The N-terminal 
sequence was confirmed by a separate analysis (Dr. Ronald Niece, 
University of Wisconsin, Madison, WI). A degenerate oligonucleotide, 
GTN GTN GGN TTY CAY GTN CTN GGN CCN AAY GCN GGN 
GAR GTN ACN CAR GGN TTY GC (N = A/G/C/T, Y = C/T and 
R = A/G) (TR5, Bio-Synthesis Labs, Lewisville, TX), was used to 
screen a AgtlI human placenta 5'-stretch cDNA library (Clontech, Palo 
Alto, CA). Approximately 2 × 105 plaques were hybridized in 0.5 M 
sodium phosphate, pH 7.2, with 10 mM EDTA, 7% sodium dodecyl 
sulfate and 1% bovine serum albumin at 50°C for 72 h with 4 ng/ml TR5 
end-labelled with [y32p]dATP using T4 polynucleotide kinase according 
to manufacturers instructions (Boehringer-Mannheim, Indianapolis, 
IN). ADNA was purified using Prep-Eze columns (5 Prime to 3 Prime 
Inc., Boulder, CO) and amplified by PCR (25 cycles, 94°C for 1 min, 
60°C for 1 min and 72°C for 1 min; 1 cycle of 72°C for 7 min) using 
2gtlI insert screening amplimers (Clontech). cDNA fragments were 
purified by Qiaex (Qiagen, Chatsworth, CA), digested with EcoRI and 
cloned into the EcoRI site of Bluescript (Stratagene, La Jolla, CA). 
cDNA was manually sequenced on both strands using Sequenase Ver- 
sion 2.0 T7 DNA polymerase (US Biochemicals, Cleveland, OH). Se- 
quence information was compiled and analyzed using the algorithms 
available through GCG (Genetics Computer Group Inc., Madison, 
WI). DNA and protein databases were searched using the computer 
programs FASTA and BLASTP performed at the NCBI (National 
Center for Biotechnology Information) using the BLAST Network 
Service (GCG). Gapped sequence alignments and identity/similarity 
comparisons were made using the computer programs PILEUP and 
GAP (GCG). 
The measurement of hioredoxin rednctase activity was by a modifi- 
cation of the method of Holmgren [29] that used the thioredoxin- 
dependent reduction of insulin with 5,5'-dithiobis-2-nitrobenzoic acid 
as the post-reaction redox chromophore, as previously described [18]. 
Antibodies were raised in rabbits using the synthetic peptide Val-Val- 
Gly - Phe -His - Val- Leu- Gly -Pro- Asn- Ala- Gly-Glu-Val-Thr-Gln-Gly- 
Phe-Ala-Ala (Macromolecular Structure Facility, University of Ari- 
zona, Tucson, AZ) derived from protein sequencing of the native en- 
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zyme. Western blots were visualized using affinity purified goat anti- 
rabbit IgG (H+L) alkaline phosphatase conjugate (BioRad). 
2.1. Expression in E. coli 
The QIAexpressionist ystem (Qiagen Inc., Chatsworth, CA) was 
used to add 6 histidine residues (6 × His) to the N-terminal end of the 
expressed protein. A PCR product was generated using cDNA frag- 
ment 30B as a template and the oligonucleotide primers (Bio-Synthesis 
Labs) GCGGATCCGATGACGATGACAAAGGCCCTGAAGAT- 
CTTCCCAAG (which includes aBamHI site, an enterokinase cleavage 
site and thioredoxin reductase sequence from base 446 to 466) and 
GCGTCGACCTACCACATGGGCTTGAGAC (which includes a 
Sail site and thioredoxin reductase sequence from 2215 to 2196). The 
PCR product was ligated into the pQE-30 vector (Qiagen) using BamHI 
and SalI restriction sites. E. coli strain M15[pRep4] was transformed 
with the thioredoxin reductase/pQE-30 construct. The 6xHis tagged 
protein was expressed after induction with isopropyl-fl-D-thiogalacto- 
side (IPTG) and purified according to the manufacturer's protocol. The 
histidine tags were removed with enterokinase according to the manu- 
facturer's instructions (Boehringer-Mannheim, Indianapolis, IN). Ex- 
pression of thioredoxin reductase as a fusion protein with glutathione 
S-transferase was accomplished using the GST Gene Fusion System 
(Pharmacia Biotech, Uppsala, Sweden). A PCR product was generated 
using clone 30B as a template and oligonucleotide primers (Bio-Synthe- 
sis Labs) GCGAATTCCTTATCAGGAGGGCAGACTTC (which in- 
cludes an EcoRI site and thioredoxin reductase sequence from base 405 
to 425) and GTCGGCCGCCTACCACATGGGCTTGAGAC (which 
includes aNotI site and thioredoxin reductase sequence from base 2196 
to 2215). The PCR product was ligated into the pGEX-4T-2 vector 
(Pharmacia Biotech) using EcoRI and NotI restriction sites. E. coli 
strain JM105 was transformed with the thioredoxin reductase/pGEX- 
4T-2 construct. The fusion product was expressed after induction with 
IPTG. Glutathione S-transferase was removed by treatment with 
thrombin and purified according to the manufacturer's instructions 
(Pharmacia Biotech). 
3. Results 
3.1. Cloning and sequence analysis 
Hybridization of a 2gtII human placenta cDNA library with 
the degenerate oligonucleotide yielded 4 positive plaques, 22, 
30A, 30B and 30C. cDNA inserts from 22 and 30C were found 
by sequence analysis to be identical 1.6 kb fragments. The other 
two cDNA inserts, 30A and 30B, with sizes of 2.4 kb and 3.7 
kb, overlapped. Clone 30A contained the reported sequence 
from base 1450 to 3826, and 30B contained the sequence from 
base 1 to 3695. Fig. 1 is a consensus of the results from 4 
separate sequencing experiments. This shows that human 
thioredoxin reductase cDNA has 3826 bases with the longest 
open reading frame starting with the ATG start codon at base 
284. An additional ATG start codon in the same reading frame 
is located at position 440. Base pair 440 was selected as the 
translational start-site depicted in Fig. 1 on the basis of its 
proximity to the N-terminal sequence of the mature protein. 
There is also a large AT-rich, 3'-untranslated region (3'-UTR) 
which includes a consensus polyadenylation sequence 
(AATAAA) immediately preceding the poly(A) tail. The pre- 
dicted amino acid sequence of thioredoxin reductase contains 
the N-terminal amino acid sequence, minus the initiating 
methionine and the first aspartate, as well as the 2 internal 
amino acid sequences identified from the purified enzyme. The 
predicted amino acid sequence of thioredoxin reductase gives 
a protein with 495 amino acids and a molecular weight of 
54,171 kDa which is slightly smaller than the experimentally 
derived molecular weights previously described [28]. Examina- 
Table 1 
Comparison of human thioredoxin reductase with other proteins 
Protein Identity Similarity High score Reference 
(%) (%) 
Glutathione reductases 
Caenorhabditis elegans (probable) 44 64 322 [35] 
E. coli 40 60 139 [36] 
Human 35 57 178 [37,38] 
Pisum sativum 38 63 148 [39] 
Saccharomyces erevisiae 37 59 138 [40] 
Burkholderia cepaeia 38 62 145 [41] 
Mus musculus 36 58 177 [37,42] 
Haemophilus influenzae 40 30 191 [43] 
Streptococcus thermophilus 41 64 148 [44] 
Glyeine max 38 61 242 [45] 
Spinacia oleraeea 35 54 235 [46] 
Thioredoxin reductases 
E. coli 24 53 65 [22] 
Streptomyces clavuligerus 23 48 46 [47] 
Arabidopsis thaliana 22 46 61 [27] 
Eubacterium acidaminophilum 31 51 77 [48] 
Penicillium chrysogenum 26 48 ND [25] 
Saccharomyces cerevisiae 23 48 ND [26] 
Other 
Human dihydrolipoamide hydrogenase 
Trypanosoma cruzi trypanothione r ductase 
Pseudomonas eruginosa mercuric reductase 
30 53 106 [49] 
36 56 138 [50] 
29 52 89 [51] 
Percentages are derived from the computer program GAP using the algorithm of Needlman and Wunsch [34]. High score refers to the maximal 
segment pair score as determined by the computer program BLASTP using the basic local alignment search tool of Altschul et al. [33]. ND represents 
scores not determined. 
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tion of  the sequence showed no consensus N-l inked glycosyla- 
tion sites (N-X-S, N-X-T). 
The cDNA and deduced amino acid sequence was used to 
search sequence databases. Several of  the most significant se- 
quence similarities are given in Table 1. Human thioredoxin 
l l )  gaat  tcgggt  ggagt  ec tg laggagggcctgatgt  c t  t eatcat  tc t  caa l t  t c t  tg taagct  e tgcqt  cr.Jg~t 9 (75) 
(76)  aaaccagac~aagccgcgagcccagggat gggagcacgcgggggacggcct gccggcggggacgacalcat t gc I  (150) 
(151) cctgggtgcageagtgtgcgtctcggggaagggaagatattttaaggcgtgtctgagcagacggggaggcttttc (225) 
(226) ca&accca~gc~gct£cgtggcgtgtgcggtttcg&cccggtcacacaaagcttcagcat~tcatgtgaggacgg (300) 
(301) tcgggccctgaaagg~icgctctcggaattggccg¢~gaa.ccgatctgcccgttgtgtttgtgaaacagagaaa (375[ 
M ~ [ -11 
1376) gataggcggcc/tggt ccaaccttgaaggct tatcagga~ggcagaet t caalagctacta&aa ATG AAC (445) 
[11 G P E D L P K S Y D Y D L I Z I G S G [191 
(446) G~C C--CT G~A C~T C~T C~C AAG TCC TAT GAC TAT GAC CTT ATC ATC ATT GGA GGT GGC (502) 
12o] s G G ~ A A A K E A ^ ~ Y G ~ K V M V t3e]  
(503} TCA GGA GGT CTG GCA GCT CCT A~ GAG GCA GCC C~ TAT GC, C /tAG AAG GTG ATG GTC (559) 
[39) L D F V T P T P L G T R W G L G G T C [57] 
(560] CTG GAC TTT GT C ACT CCC ACC CCT CTT GGA ACT AGA TGG GGT CTT GGA GGA ACA TGT (616) 
[58~ v N V G C I P K K L M H Q A A L b G Q [76] 
(617} GTG AAT GTG GGT TGC ATA CCT AAA AAA CTG ATG CAT CAA GCA GCT TTG TTA GGA CAA (~73) 
[771 A L Q D $ R N Y G w K V E E T V K H D (95] 
(6741 GCC CTG CAA GAC TCT CGA AAT TAT GGA TGG A~ GTC GAG GAG ACA GTT AAG CAT CAT (730) 
[96~ W D R M I E A V Q N H I G S L N W G Y [114] 
(731] TGG GAC AGA ATG ATA GAA GCT GTA CAG AAT CAC ATT GGC TCT TTG AAT TGG GGC TAC (757) 
[ l lb l  ~ V A L R E K K V V r E N A Y G 0 r I 1133] 
(758} CGA GTA GCT CTG CGG GAG #~%A ~ GTC GTC TAT GAG AAT GCT TAT GGG C~ TTT ATT ~844) 
[134] G P H R I K A T N N K G K E H I Y S A [152] 
(845} GGT CCT CAC AGG ATT AAG GCA ACA AAT AAT ~J~ GGC AAA GAA A~ ATT TAT TCA GCA ~901) 
[153] E $ F L I A T G E R P R y L G I P S S [171] 
(902} GAG AGT T~T C~ A~T G~C A-CT G~ G--AA AGA CCA CGT TAC TTG GGC ATC CCT GGT GAC ~958) 
[172[ K E Y C I S S D D L F S L P Y C P G K [190] 
(9591 A~ C~A TAC TC.C ATC AGC AGT GAT GAT CTT TTC TCC TTG CCT TAC TC,~ CCG GGT AAG (I015) 
[1911 T C V V G A S Y V A L E C A G F L A G [209] 
(1016) ACC CTG GTT GTT GGA GCA TCC TAT GTC GCT TTG GAG TGC GCT GGA TTT CTT GCT GGT (10721 
[210] I G L G V T V M V R S I L L R G F D Q [228] 
[1073) ATT GGT TTA GGC GTC ACT GTT ATG GTT ~G TCC ATT CTT CTT AGA GGA TTT GAC CAG [11291 
[229] D M A N K I G E H M E E H G I K F I R [247] 
(1130) GAC ATG GCC AAC AAA ATT GGT GAA CAC ATG GAA GAA CAT GGC ATC AAG TTT ATA AGA {i186) 
[2~S[ Q r V p I K V ~ ~ I ~ A G T e ~ R 5 ~ [266[ 
(i157) CAG TIC GTA CCA ATT AAA GTT GAA CAA ATT GAA GCA GGG ACA CCA GGC CGA CTC AGA {1243) 
[267] V V A Q S T N $ E E I I E G E Y N T V 1285) 
(1244) GTA GTA C~T CAG TCC ACC AAT AGT GAG GAA ATC ATT GAA GGA GAA TAT AAT ACG GTG [1300) 
[286) M L A I G R D A C T R K I G L E T V G 13041 
(1301} ATG CTG GCA ATA GGA AGA GAT GCT TGC ACA AGA ~ ATT GGC TTA C~ ACC GTA GGG {1357) 
[305] V K I N E K T G • K I P v T D E E Q T N 1323| 
11358) GTG AAG ATA AAT GAA AAG ACT GGA AAA ATA CCT GTC ACA &AT GAA C, AA CAG ACC AAT (1414) 
[324] v P Y I Y A I G D I L E D K v E L T e [342] 
(14151 GTG CCT TAC ATC TAT SCC ATT GGC GAT ATA TTG GJ&G CAT AAG GTG GAG CTC ACC CCA 11471) 
1343] V A ] Q A G R L L A Q R L Y A G S T V [361] 
(147~I GTT GCA ATC CAG GCA GGA AGA TTG CTG GCT C~ AGG CTC TAT GCA GGT TCC ACT GTC 11538) 
1362) K C D Y E N V P T T V F T P L E Y G A {380] 
(1529) AAG TGT GAC TAT GAA AAT GTT CCA ACC ACT GTA TTT ACT CCT TTG C, AA TAT GGT GCT 115~5) 
]38 I [  C G L $ E E K A V E ~ r S E E N I E V [3991 
115861 TGT GGC CTT TCT GAG GAG AAA GCT GTG GAG AAG TTT GGG GAA GAA AAT ATT GAG GTT ~1642) 
[400] Y H S Y F W P L E W T I P S R D N M K [418] 
[1643) TAC CAT AGT TAC TTT TGG CCA TTG GAA TGG ACG ATT CCG TCA AGA GAT AAC AAC A~A (1699) 
[419] C Y A K I I C N T K D N E R V V G F H [437] 
{1700) TGT TAT GCA AAA ATA ATC TGT AAT ACT A~ GAC ~T C~ CGT G~ G~G G~C T~T CAC ~1756) 
[438] V L G P N A G E V T ~ G F A A A L K C [456] 
(1757p GTA CTG GGT CCA AAT GCT GGA GAA GTT ACA CAA GGC TTT GCA GCT GCG CTC ~AA tgt (18131 
[4571 G L T K K Q L D S T 1 S I H P V C A E [¢75]  
(15141 GGA CTG ACC AAA AAG CAG CTG ~AC AGC ~ ATT GGA ATC CAC CCT GTC TGT GCA ~S (1870} 
(4761 V F T T L S V T K ~ S G A S I L Q A G [494) 
(1871) GTA TTC ACA ACA TTG TCT GTG ACC AAG CGC TCT GGG GCA AGC ATC CTC CAG GCT GGC (1927) 
[4951 C end [4951 
(1928} TGC TGA 9gttaagcccc&qtgtggatgctgttgcca~gactgcaaaccactggctcgtttccgt~cccaaatc ~2000] 
{2001) caag~cga&gttttctagigggttcttgggc~cttggcacctgcgtgtcctgtgcttaccaccgcccaaggcccc 12075] 
(2076[ cttggatctcttggltaggagttggtgaatagaaggcaggcagcatcacactggggtcactgacagacttgaagc ~2150) 
(2151} tgacatttggcagggcatcgaagggatgcatccatgaagteaccagtctcaagcccatgtggtaggcggtgatg 9 ~2225) 
(2226) aacaactgtcaaatcagttttagcatgaccttt¢¢ttgtggattttcttattctcqttgtcaagttttctagggt (2300) 
(230~) tgaat~tttttcttttttctcca~gqtg~taatgatittagagatgaaa~cgttagcagttgatttt~gtcc&a ~2375) 
(23761 aa~caagtcatggctagagtatccatgcaaggtgtcttgttgcatggaagggataqttt9gctccctt~gaggct (2430( 
(2451] at~taggcttgtcccgggaaagagaactgtcctgc~gctgaaltggactgttctttactgacctgctcageagtt ~2525) 
(2526) tcttctctcatatattcccaaaacaagt~catctgcgatc~actctagcc~aatttgcccctgtgtgctacatga ~2600) 
(2601) tggatglttattattttaaggtetgtttlqgaagggaaatggctacttggccagccattgcctggcatttggta 9 (2675) 
(~676) t&tag~atgattctciccat~atttgtc&tggaggcagacatacacc~gaaatggg~gagaaacagtacatatct ~2750} 
(2751) ttctgtctttagtttlt~otgtgctggtctaagcaagctga@atcatttgcaatggaaaacacgtaacttgttta (2825) 
(2526) allgtttttctg@tlgctttagctttatgctaaaaiaaataatgacattgggtatct&tttctttctaagacata ~29001 
(2901) cattagtaggaaaitllgt ct t ttcatgctZatgat ttagctgt tt tg~ggt aat tgctttttaaaggaagttat (2975( 
~2976) taatat  c . taagt  ta t  ta t  t .a ta t t  t tgaacac lggtgg~t  g tg~ag?at t  t teat  t t~a laaccaagt  ggt t  t (30301 
{3051) tgact  t tc tc tg t tgaatgaacaactgtgcct tg tggaat  t t  t tgc&g lagtgt  t a tgc t t tg t  t lgcat  t tca  (31251 
{3126) acttgcattattataaagaggtattaatgcetcagttatgtgtttgtcaatgtactggctgaggattctatctca (32001 
~3201) gctgtc t t t tc t lac tqtgt iggt tgagt t t tg i l c i cgtect tg tggacatcagcctcc tgccagcagt tc t tg  (32751 
~32761 aagct tc t  t t t t eat  tcc tgctact  c t l cc tgtat  t t  c t  cagt  tgcagcaetg lg tggt  ca&aat lcat  t t c tgg  (33501 
~3351} gccacctclgggl icccatgcatctgcctggcatttaggcagcagigcccctgiccgtcccccacaggctc~gcc {3425 l  
(3426) tc icgtcctc i tc tcat t tgqctgtgt la lgaa l tggg i~algggaaalggagagagca l t tgaggcagttg&cc (3500) 
{3501) ~tat  t cagt t t t  a t t ta t  t ta t  t t t ta&t t  tg t t t  t t c t  c tccaagtccacc&gt  e tc t~aaat  t lgaaeagtag  (35'75) 
(3576 l  9cggtatgagataatcaggcct  aat  catgt  tg tg&t  to t  c t  t t  to t  tagCggagtggaat  g t  te ta tccecacaa  (3650)  
(3651) gaaggat~ats tc t ta tagact tg tc t tg t tcagat tc tgtat t ta¢¢cat t t ta t tgaaacatatactaagt tc  (3725) 
(3726) catgtatttttqttlcaaatcttctqilalaaaacaaaacaatgtgaaacattaaaattaaaaggcattaataet {3800)  
(3801) aaa~aaaaaaaa~aalacccgaattc 
Fig. 1. Nucleotide sequence and deduced amino acid sequence of 
human thioredoxin reductase. Nucleotide residues are numbered from 
(1) to (3826) while amino acids are number from [-2] to [495] with the 
ATG triplet encoding the proposed initiating methionine residue num- 
bered [-2]. Residues underlined correspond to sequences confirmed by 
the peptide sequencing and N-terminal sequencing of the native enzyme 
isolated from human placenta. The calculated molecular mass of the 
mature enzyme is 54,171. 
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Msglu YTAPHILIATGGMPSTPHESQIpGA 5LGIT $DGFFQLEELPGRSVIVGAGYIAVEMAGILSALGSKTSLMI 217 
Ecglu ITAEHILIATGGRPSHP DIpGV EYGID SDGFFALPALPERVAWGAGYIAVELAGVINGLG~THLFV 197 
Mstrx  KEKI ySA~S FLIATGERPRYL GI PGDKEYCIS 3 D DL FS L P YC pGKTLVVGAS YVALECAG FLAG I GLG% ~FVMV 218 
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Pct rx  SEP%'RT~.DAVI IATC~LNLpGEETyWQNGISACAVCDGAVpI  FRNKPLYVIGGGDSJ~EFJ~MFLA/~YGSS%rFVLV 155 
• + ++ + + + N~F2 . .+ 
Hlglu RHDK%rLRSFDSMISTNCTEELENAGVEVLKFSQVKE %rKKTLSGLEVSM~TAVPGRLPVMTMIPDVDCLLWAIGRVPNT 295 
Ecglu RKHAP L RS FD PMI $ET LVEV~AE GPQ LHTNAI P KAVV~T DG S LTLELEDGRS E TVDCLIWAI GREpAN 267 
HstIx R S ILLRGFDQD~KIGE~EZHGIKF IRQFVP IK  VEQIEAGTPGRLRWAQSTNSEEIIEGEYNTVMLAIGRDACT 295 
Ceglu R S IPLKGFDRDC~FVMEHLKTTG~EH VE VERV~VGSKKKVTFTGNGGVE EYDT%qWAAGRVPNL 296 
Ectrx RRDG FRA EKILIKRLMDKVENGNIILhTNRTLEKVTGDQMG VTGVRLRDTQNSDNIESLDVAGLFVAIGHSPNTA 250 
Pctzx RKDK LRA SNIMADRLL AHPKCK~FNTVAT~IG£NKPNGLMTHLR%rI(D%rL SNAEEV%/I~GLFYAVGHDPASG 261 
. . + ÷ +. . .  +.+ 72~I  , ++ 
Hsglu KDLSLNKLGIQTDDK GHIZVDEFQNTNVKGIYAVGDVC G KALLTPVAIAAGRKLAHRLFEYKEDSKLDYNNZP 368 
Ecglu DNINLEAAGVKTNEK GYIVVDKyQNTNIKGIYAVGDNT G AVELTP%IAVAAGRRLSERLFNNKPDEHLDYSNIP 340 
Hst rx  RKIGLETVG~INEKTGKIPVTDEEQTNVPyIYAIGDILED K~LTPVAIQAGRLLAQRLYAGSTV KCDYEMVP 369 
Ceglu KSLNLDNAGgRTDKRSGKILADEFDP~CNGVYAVGDIVQD RQELTPLAIQSGKLLADRLFSNSKQ IVRFDG~A 370 
Ectrx IFEGQLELEN GYIKVQSG IHGNATQTSIPGVFAAGDV~HIYRQAITSAGTGCMAALDAERYL DGL~ 321 
Pctrx LVKGQ~LDDEGYI ITKPG TSFTMVEGVFACGDVQDKRYRQAITSAGSGCVA~AEKFIAETETHQ~AKPVL 334 
+ ++ ++ + + + + + + + + + + + 
Hsglu TWFSHPPIGTVGLTEDEAIHXYGIENV~YSTSFTpM'fMAVTKRKTK CV~C~KE E}CgVGIHMQ~LGCD~4LQ 445 
Ecglu TWFSHPPIGTVGLTEPQAREQYGDDOVKVYKSSFTAMYTAVTTHRQP CP4MKLVCVGSE EKIVGIHGIGFGMD~4LQ 417 
Hst rx  TTVFTpLEYGACGLSEEKAVEKFGEENIEVYHSYFWPLEWTIP SRDNNKCY;C4IICNTKDNERWGFHVLGPNAGEVTQ 448 
Ceglu TTVFTp LELSTVGLTEEEAIQKHGEDS I [VFHSHFT PFEYVVpQN KDSGFCYVKAVCTRDESQKI LGLHFVGPN2Q%EVI Q 450 
Ket rx  
ect,x 
+ + + + +++ + I< 
Hsglu GFAVAV~GATKADFDNTVAIHPTSSEELVTLR 478 
Ecglu GFAVAL~GATKKDFDNTVAIHPTAAEEFVTMR 450 
Hst rx  GFAAALKCGLTKKQLDSTIGIHFVCAEVFTTLSVTKRSGASILQAGC 495 
Ceglu GYAVAFRVGISMSDLQNTIAIMPCSSEEFVKLHITKRSGQDPRTQGCCG 499 
£ctr× 
Pctrx 
Fig. 2. Progressive gapped alignment of related sequences: 
Hsglu = human glutathione reductase [37,38], Ecglu = E. coli glutathi- 
one reductase [36], Hstrx--human thioredoxin reductase, Ceglu = 
C. elegans probable glutathione reductase [35], Ectrx = E. coli thiore- 
doxin reductase [22], Pctrx = P. chrysogenum thioredoxin reductase 
[25]. Identical residues are indicated by dots (e); + indicates residues 
conserved among Hsglu, Ecglu, Hstrx and Ceglu, with # indicating 
their active-site cysteines. % indicates active site cysteines of Ectrx and 
Pctrx. Underlined residues are probable FAD binding regions ADP 
(1242; ADP) and Flavin (322-332; flavin) of Hstrx on the basis of 
similarity to human glutathione reductase. ~-., indicates domain bound- 
aries of Hstrx as determined by sequence comparison with Hsglu with 
F1 and F2 representing the FAD domain, N the NADPH domain and 
I the interface domain. 
reductase is most similar to a deduced protein sequence derived 
from genomic sequencing of Caenorhabditis elegans, identified 
as a probable glutathione reductase (Fig. 2). Sequence identity 
to a number of  eukaryotic and prokaryotic glutathione reduc- 
tases ranges from 35% to 44%, and for thioredoxin reductases 
23% to 31%. Identity to other pyridine nucleotide-disulfide 
oxidoreductases was 29% to 36%. Genetic distance measure- 
ments between all sequences listed in Table 1 favor a pairwise 
alignment between human thioredoxin reductase and C. ele- 
gans glutathione reductase, indicating that the C. elegans se- 
quence is likely to be a thioredoxin reductase. 
3.2. Protein expression 
Expression of  the cDNA in E. coli as either a glutathione 
S-transferase fusion protein or with a 6 x His tag yielded a 
protein product that co-migrated on SDS-PAGE and was im- 
munologically indistinguishable from the native protein (Fig. 
3). However, the purified protein had no thioredoxin reductase 
activity and spectral analysis showed no absorption at 450 nm 
characteristic of bound FAD. 
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Fig. 3. Western blot of thioredoxin reductase run on an 8% SDS-PAGE 
gel. W represents pure thioredoxin reductase isolated from human 
placenta, and RX represents hioredoxin reductase expressed inE. coli 
as a fusion protein with glutathione S-transferase (GST) after emoval 
of GST. 
4. Discussion 
We report the cloning of cDNA for human thioredoxin re- 
ductase from a human placenta library. This represents he first 
sequence available for thioredoxin reductase cDNA from a 
higher-order eukaryote. The deduced amino acid sequence 
clearly identifies the protein as a member of the pyridine-nucle- 
otide-disulfide r ductase family with a strong resemblance, up 
to 44% identity, to reported glutathione reductases. Similarity 
to reported thioredoxin reductases from prokaryotes and 
lower-order eukaryotes (plants and fungi) is lower, but still 
significant (Table 1). 
It was expected that mammalian thioredoxin reductases, 
with an estimated subunit molecular weight of 58 kDa for the 
bovine enzyme [2] and 65 kDa for the human enzyme [28], 
would have a different domain structure than the smaller 35 
kDa bacterial thioredoxin reductases. While structural details 
can only be estimated from sequence information, comparisons 
to proteins where structural information exists can be predic- 
tive. Extensive structural information derived from X-ray crys- 
tal data is available for human glutathione reductase [30,31] 
and E. coli thioredoxin reductase [32]. It is, therefore, possible 
to compare their sequences with the putative human thiore- 
doxin reductase we have cloned and to infer a structure of the 
reported sequence. A gapped sequence alignment [33] with se- 
lected thioredoxin reductases and glutathione reductases (Fig. 
2) delineates the regions of similarity with human thioredoxin 
reductase. 
The domain structure of the putative human thioredoxin 
reductase is proposed to be similar to glutathione reductase 
based on sequence comparison (Fig. 4). The features that dis- 
tinguish E. coli thioredoxin reductase from human glutathione 
reductase are mirrored in the comparison between E. coli 
thioredoxin reductase and human thioredoxin reductase. Most 
of the size difference between human thioredoxin reductase and 
the smaller bacterial enzyme can be attributed to the presence 
of a dimer interface domain. The redox active cysteines of 
human thioredoxin reductase are located in the FAD domain 
with a 4-amino acid bridge between cysteines. The active site 
disulfide of E. coli thioredoxin reductase, on the other hand, is 
part of the NADPH domain with only a 2-amino acid bridge 
between cysteines. It is reasonable to surmise that the 3-dimen- 
sional structure will be very similiar to glutathione reductase. 
To further study the enzyme, we attempted to express the 
active enzyme in E. coli. While we were able to detect expres- 
sion of the protein by Western blotting utilizing 2 distinct ex- 
pression systems, we were unable to detect hioredoxin reduc- 
tase activity in either case. The protein also had no glutathione 
reductase activity. The expressed protein co-migrated with the 
native enzyme on SDS-PAGE as expected but lacked the 450 
nm absorption maxima that would be expected if the enzyme 
contained FAD. The inability to bind FAD may be related to 
incorrect folding of the protein by E. coli expression system 
since all the structural sequence components for effective FAD 
binding are present. Further work will pursue expression of the 
enzyme in other eukaryotic systems in order to provide defini- 
tive evidence that the cDNA we have cloned is indeed thiore- 
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Fig. 4. Proposed omain structure of human thioredoxin reductase (Hstrx) compared tohuman glutathione r ductase (Hsglu) and E. coli thioredoxin 
reductase (Ectrx). 
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